Effects of sitagliptin on peritoneal membrane: The potential role of mesothelial cell tight junction proteins
CONCLUSION: The expression of TJ proteins including claudin-1 and claudin-15 was associated with transport function both in HPMCs and in a rat model of PD. Sitagliptin prevents peritoneal fibrosis in PD and can potentially restore peritoneal mesothelial cell TJ proteins.PMID:36998201 | DOI:10.1177/08968608231158224 (Source: Peritoneal Dialysis International)
Source: Peritoneal Dialysis International - March 31, 2023 Category: Urology & Nephrology Authors: Chor Ho Jo Sua Kim Tae Kyung Ha Duk-Hee Kang Gheun-Ho Kim Source Type: research
Stimulatory effect of imeglimin on incretin secretion
ConclusionsOur data suggest that the imeglimin-induced increase in plasma GLP-1 levels likely contributes at least in part to its stimulatory effect on insulin secretion. (Source: Journal of Diabetes Investigation)
Source: Journal of Diabetes Investigation - March 28, 2023 Category: Endocrinology Authors: Quan Yingyue,
Kenji Sugawara,
Harumi Takahashi,
Norihide Yokoi,
Kento Ohbayashi,
Yusaku Iwasaki,
Susumu Seino,
Wataru Ogawa Tags: Original Article Source Type: research
Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity
Biomed Pharmacother. 2023 Mar 24;162:114555. doi: 10.1016/j.biopha.2023.114555. Online ahead of print.ABSTRACTThe standard regimen treatment has improved GBM outcomes, but the survival rate of patients is still unsatisfactory. Temozolomide (TMZ) resistance is one of main reasons limiting the therapeutic efficacy of GBM. However, there are currently no TMZ-sensitizing drugs available in the clinic. Here we aimed to study whether the antidiabetic drug Sitagliptin can inhibit the survival, stemness and autophagy of GBM cells, and thus enhance TMZ cytotoxicity. We used CCK-8, EdU, colony formation, TUNEL and flow cytometry ass...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 26, 2023 Category: Drugs & Pharmacology Authors: Fangting You Cheng Li Shicheng Zhang Qiaoshan Zhang Zhiyuan Hu Yuhui Wang Tong Zhang Qingming Meng Rutong Yu Shangfeng Gao Source Type: research
Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity
Biomed Pharmacother. 2023 Mar 24;162:114555. doi: 10.1016/j.biopha.2023.114555. Online ahead of print.ABSTRACTThe standard regimen treatment has improved GBM outcomes, but the survival rate of patients is still unsatisfactory. Temozolomide (TMZ) resistance is one of main reasons limiting the therapeutic efficacy of GBM. However, there are currently no TMZ-sensitizing drugs available in the clinic. Here we aimed to study whether the antidiabetic drug Sitagliptin can inhibit the survival, stemness and autophagy of GBM cells, and thus enhance TMZ cytotoxicity. We used CCK-8, EdU, colony formation, TUNEL and flow cytometry ass...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 26, 2023 Category: Drugs & Pharmacology Authors: Fangting You Cheng Li Shicheng Zhang Qiaoshan Zhang Zhiyuan Hu Yuhui Wang Tong Zhang Qingming Meng Rutong Yu Shangfeng Gao Source Type: research
Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity
Biomed Pharmacother. 2023 Mar 24;162:114555. doi: 10.1016/j.biopha.2023.114555. Online ahead of print.ABSTRACTThe standard regimen treatment has improved GBM outcomes, but the survival rate of patients is still unsatisfactory. Temozolomide (TMZ) resistance is one of main reasons limiting the therapeutic efficacy of GBM. However, there are currently no TMZ-sensitizing drugs available in the clinic. Here we aimed to study whether the antidiabetic drug Sitagliptin can inhibit the survival, stemness and autophagy of GBM cells, and thus enhance TMZ cytotoxicity. We used CCK-8, EdU, colony formation, TUNEL and flow cytometry ass...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 26, 2023 Category: Drugs & Pharmacology Authors: Fangting You Cheng Li Shicheng Zhang Qiaoshan Zhang Zhiyuan Hu Yuhui Wang Tong Zhang Qingming Meng Rutong Yu Shangfeng Gao Source Type: research
Pharmacokinetic comparison of sitagliptin and metformin HCl extended-release tablets versus JANUMET ® XR in healthy volunteers under fasting and fed conditions
Conclusion: The results demonstrated for the first time that sitagliptin 100 mg and metformin 1000 mg produced by Nanjing Chia-Tai Tianqing Pharmaceutical Company was bioequivalent to the branded Janumet® XR, and both drugs were well tolerated. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - March 22, 2023 Category: Drugs & Pharmacology Source Type: research
Vascular and metabolic effects of ipragliflozin versus sitagliptin in type 2 diabetes treated with sulfonylurea and metformin: IVS study
CONCLUSIONS: Ipragliflozin add-on therapy can be a viable option for better glycemic control with multiple vascular and metabolic benefits in patients with type 2 diabetes who are inadequately controlled with metformin and sulfonylurea. This article is protected by copyright. All rights reserved.PMID:36932823 | DOI:10.1111/dom.15056 (Source: Atherosclerosis)
Source: Atherosclerosis - March 18, 2023 Category: Cardiology Authors: Seon Mee Kang Han Mi Yun Minji Sohn Soo Lim Source Type: research
Vascular and metabolic effects of ipragliflozin versus sitagliptin in type 2 diabetes treated with sulfonylurea and metformin: IVS study
CONCLUSIONS: Ipragliflozin add-on therapy can be a viable option for better glycemic control with multiple vascular and metabolic benefits in patients with type 2 diabetes who are inadequately controlled with metformin and sulfonylurea. This article is protected by copyright. All rights reserved.PMID:36932823 | DOI:10.1111/dom.15056 (Source: Atherosclerosis)
Source: Atherosclerosis - March 18, 2023 Category: Cardiology Authors: Seon Mee Kang Han Mi Yun Minji Sohn Soo Lim Source Type: research
Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase ‐4 inhibitors: A population‐based cohort study using Japanese Latter‐Stage Elderly Healthcare Database
ConclusionsNot all the DPP-4 inhibitors could induce bullous pemphigoid significantly. Therefore, the association warrants further investigations before generalization. (Source: Journal of Diabetes Investigation)
Source: Journal of Diabetes Investigation - March 10, 2023 Category: Endocrinology Authors: Yumi Harano,
Yasutaka Mitamura,
Peng Jiang,
Takako Fujita,
Akira Babazono Tags: Original Article Source Type: research
Enhancing endogenous levels of GLP1 dampens acute olanzapine induced perturbations in lipid and glucose metabolism
Olanzapine is a second-generation antipsychotic (SGA) used in the treatment of schizophrenia and several on- and off-label conditions. While effective in reducing psychoses, acute olanzapine treatment causes rapid hyperglycemia, insulin resistance, and dyslipidemia and these perturbations are linked to an increased risk of developing cardiometabolic disease. Pharmacological agonists of the glucagon-like peptide-1 (GLP1) receptor have been shown to offset weight-gain associated with chronic SGA administration and mitigate the acute metabolic side effects of SGAs. The purpose of this study was to determine if increasing endo...
Source: Frontiers in Pharmacology - March 1, 2023 Category: Drugs & Pharmacology Source Type: research
IDF2022-1118 A comparative effect of DPP4 inhibitor and GLP-1 agonist on lipid profile among obese patients with DMT2
Dyslipidemia seems to be one of the major factors leading to cardiovascular mortality, especially in patients suffering from Diabetes Mellitus type 2 (DMT2). We decided to observe the effects of hypoglycemic agents- Dipeptidyl peptidase 4 (DPP4) inhibitors (Sitagliptin) or Glucagon like peptide 1 (GLP-1) agonists (Liraglutide) not just on glycemic level, but also on lipid profile in our patients suffering from obesity, dyslipidemia and DMT2. (Source: Diabetes Research and Clinical Practice)
Source: Diabetes Research and Clinical Practice - March 1, 2023 Category: Endocrinology Authors: N. Bostoganashvili, K. Mikadze, R. Kvanchakhadze, S. Tukvadze Tags: Diabetes in Women Source Type: research
Hypoglycemic medicines in the treatment of Alzheimer ’s disease: Pathophysiological links between AD and glucose metabolism
Alzheimer’s Disease (AD) is a global chronic disease in adults with beta-amyloid (Aβ) deposits and hyperphosphorylated tau protein as the pathologic characteristics. Although the exact etiology of AD is still not fully elucidated, aberrant metabolism including insulin signaling and mitochondria dysfunction plays an important role in the development of AD. Binding to insulin receptor substrates, insulin can transport through the blood-brain barrier (BBB), thus mediating insulin signaling pathways to regulate physiological functions. Impaired insulin signaling pathways, including PI3K/Akt/GSK3β and MAPK pathways, could c...
Source: Frontiers in Pharmacology - February 23, 2023 Category: Drugs & Pharmacology Source Type: research
